Main Menu

Publications

Publications Highlights View all by category

Types of Publications


Journal Articles

Ludwig, H. Boccadoro, M. Moreau, P. San-Miguel, J. Cavo, M. Pawlyn, C. Zweegman, S. Facon, T. Driessen, C. Hajek, R. Dimopoulos, M.A. Gay, F. Avet-Loiseau, H. Terpos, E. Zojer, N. Mohty, M. Mateos, M.-. Einsele, H. Delforge, M. Caers, J. Weisel, K. Jackson, G. Garderet, L. Engelhardt, M. van de Donk, N. Leleu, X. Goldschmidt, H. Beksac, M. Nijhof, I. Abildgaard, N. Bringhen, S. Sonneveld, P. (2021). Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, Vol.35 (1), pp. 31-44.  show abstract

Messiou, C. Porta, N. Sharma, B. Levine, D. Koh, D.-. Boyd, K. Pawlyn, C. Riddell, A. Downey, K. Croft, J. Morgan, V. Stern, S. Cheung, B. Kyriakou, C. Kaczmarek, P. Winfield, J. Blackledge, M. Oyen, W.J. Kaiser, M.F. (2021). Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. Radiology: imaging cancer, Vol.3 (5), pp. e210048-e210048.

Brown, S. Pawlyn, C. Tillotson, A.-. Sherratt, D. Flanagan, L. Low, E. Morgan, G.J. Williams, C. Kaiser, M. Davies, F.E. Jenner, M.W. (2021). Bortezomib, Vorinostat, and Dexamethasone Combination Therapy in Relapsed Myeloma: Results of the Phase 2 MUK four Trial. Clinical lymphoma myeloma and leukemia, Vol.21 (3), pp. 154-161.e3.

Jones, J.R. Pawlyn, C. Jackson, G.H. (2021). Safety of lenalidomide for maintenance treatment of patients with multiple myeloma following autologous stem cell transplantation. Expert opinion on drug safety, Vol.20 (10), pp. 1137-1145.

Terpos, E. Raje, N. Croucher, P. Garcia-Sanz, R. Leleu, X. Pasteiner, W. Wang, Y. Glennane, A. Canon, J. Pawlyn, C. (2021). Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. Blood advances, Vol.5 (3), pp. 725-736.  show abstract

Bird, S. Cairns, D. Menzies, T. Boyd, K. Davies, F. Cook, G. Drayson, M. Gregory, W. Jenner, M. Jones, J. Kaiser, M. Owen, R. Jackson, G. Morgan, G. Pawlyn, C. (2021). Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial. Clinical lymphoma myeloma and leukemia, Vol.21 (10), pp. 667-675.

Jackson, G.H. Pawlyn, C. Cairns, D.A. de Tute, R.M. Hockaday, A. Collett, C. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Rocci, A. Snowden, J.A. Jenner, M.W. Cook, G. Russell, N.H. Drayson, M.T. Gregory, W.M. Kaiser, M.F. Owen, R.G. Davies, F.E. Morgan, G.J. UK NCRI Haemato-oncology Clinical Studies Group, (2021). Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. Plos medicine, Vol.18 (1), pp. e1003454-?.  show abstract

Bird, S. Panopoulou, A. Shea, R.L. Tsui, M. Saso, R. Sud, A. West, S. Smith, K. Barwood, J. Kaczmarek, E. Panlaqui, C. Kaiser, M. Stern, S. Pawlyn, C. Boyd, K. (2021). Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. The lancet. haematology, .

Pawlyn, C. Cairns, D. Kaiser, M. Striha, A. Jones, J. Shah, V. Jenner, M. Drayson, M. Owen, R. Gregory, W. Cook, G. Morgan, G. Jackson, G. Davies, F. (2020). The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial. Leukemia, Vol.34 (2), pp. 604-612.  show abstract

Pawlyn, C. Cairns, D. Menzies, T. Jones, J. Jenner, M. Cook, G. Boyd, K. Drayson, M. Kaiser, M. Owen, R. Gregory, W. Morgan, G. Jackson, G. Davies, F. (2020). Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial. Haematologica, Vol.Online ahead of print, pp. 0-?.  show abstract

Jackson, G.H. Davies, F.E. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Waterhouse, A. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Allotey, D. Shafeek, S. Jenner, M.W. Cook, G. Russell, N.H. Kaiser, M.F. Drayson, M.T. Owen, R.G. Gregory, W.M. Morgan, G.J. UK NCRI Haematological Oncology Clinical Studies Group, (2020). Lenalidomide before and after ASCT for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial. Haematologica, .  show abstract

Mian, H. Grant, S.J. Engelhardt, M. Pawlyn, C. Bringhen, S. Zweegman, S. Stege, C.A. Rosko, A.E. von Lilienfeld-Toal, M. Wildes, T.M. (2020). Caring for older adults with multiple myeloma during the COVID-19 Pandemic: Perspective from the International Forum for Optimizing Care of Older Adults with Myeloma. Journal of geriatric oncology, Vol.11 (5), pp. 764-768.

Bygrave, C. Pawlyn, C. Davies, F. Craig, Z. Cairns, D. Hockaday, A. Jenner, M. Cook, G. Drayson, M. Owen, R. Gregory, W. Morgan, G. Jackson, G. Kaiser, M. (2020). Early relapse after high-dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high-risk disease in multiple myeloma. British journal of haematology, .  show abstract

Jackson, G.H. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Waterhouse, A. Jones, J.R. Wilson, J. Taylor, C. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Jenner, M.W. Cook, G. Russell, N.H. Drayson, M.T. Kaiser, M.F. Owen, R.G. Gregory, W.M. Davies, F.E. Morgan, G.J. UK NCRI Haemato-oncology Clinical Studies Group, (2020). Optimising the value of immunomodulatory drugs during induction and maintenance in transplant ineligible patients with newly diagnosed multiple myeloma: results from Myeloma XI, a multicentre, open-label, randomised, Phase III trial. British journal of haematology, .  show abstract

Rana, R. Cockwell, P. Drayson, M. Cook, M. Pratt, G. Cairns, D.A. Pawlyn, C. Jackson, G. Davies, F. Morgan, G. Pinney, J.H. (2020). Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood advances, Vol.4 (22), pp. 5836-5845.  show abstract

Bradbury, C.A. Craig, Z. Cook, G. Pawlyn, C. Cairns, D.A. Hockaday, A. Paterson, A. Jenner, M.W. Jones, J.R. Drayson, M.T. Owen, R.G. Kaiser, M.F. Gregory, W.M. Davies, F.E. Child, J.A. Morgan, G.J. Jackson, G.H. (2020). Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood, Vol.136 (9), pp. 1091-1104.  show abstract

Jackson, G.H. Davies, F.E. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Hockaday, A. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Jenner, M.W. Cook, G. Russell, N.H. Kaiser, M.F. Drayson, M.T. Owen, R.G. Gregory, W.M. Morgan, G.J. UK NCRI Haemato-oncology Clinical Studies Group, (2019). Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The lancet. oncology, Vol.20 (1), pp. 57-73.  show abstract

Pawlyn, C. Jackson, G.H. (2019). Physicians, paraproteins and progress: diagnosis and management of myeloma. British journal of hospital medicine (london, england : 2005), Vol.80 (2), pp. 91-98.  show abstract

Pawlyn, C. Davies, F.E. (2019). Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood, Vol.133 (7), pp. 660-675.  show abstract

Cook, G. Royle, K.-. Pawlyn, C. Hockaday, A. Shah, V. Kaiser, M.F. Brown, S.R. Gregory, W.M. Child, J.A. Davies, F.E. Morgan, G.J. Cairns, D.A. Jackson, G.H. (2019). A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study. The lancet. haematology, Vol.6 (3), pp. e154-e166.  show abstract

Jones, J.R. Weinhold, N. Ashby, C. Walker, B.A. Wardell, C. Pawlyn, C. Rasche, L. Melchor, L. Cairns, D.A. Gregory, W.M. Johnson, D. Begum, D.B. Ellis, S. Sherborne, A.L. Cook, G. Kaiser, M.F. Drayson, M.T. Owen, R.G. Jackson, G.H. Davies, F.E. Greaves, M. Morgan, G.J. NCRI Haemato-Oncology CSG, (2019). Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients. Haematologica, Vol.104 (7), pp. 1440-1450.  show abstract

Jackson, G.H. Davies, F.E. Pawlyn, C. Cairns, D.A. Striha, A. Collett, C. Waterhouse, A. Jones, J.R. Kishore, B. Garg, M. Williams, C.D. Karunanithi, K. Lindsay, J. Wilson, J.N. Jenner, M.W. Cook, G. Kaiser, M.F. Drayson, M.T. Owen, R.G. Russell, N.H. Gregory, W.M. Morgan, G.J. UK NCRI Haematological Oncology Clinical Studies Group, (2019). Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. The lancet. haematology, Vol.6 (12), pp. e616-e629.  show abstract

Shah, V. Sherborne, A.L. Walker, B.A. Johnson, D.C. Boyle, E.M. Ellis, S. Begum, D.B. Proszek, P.Z. Jones, J.R. Pawlyn, C. Savola, S. Jenner, M.W. Drayson, M.T. Owen, R.G. Houlston, R.S. Cairns, D.A. Gregory, W.M. Cook, G. Davies, F.E. Jackson, G.H. Morgan, G.J. Kaiser, M.F. (2018). Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia, Vol.32 (1), pp. 102-110.  show abstract

Gay, F. Jackson, G. Rosiñol, L. Holstein, S.A. Moreau, P. Spada, S. Davies, F. Lahuerta, J.J. Leleu, X. Bringhen, S. Evangelista, A. Hulin, C. Panzani, U. Cairns, D.A. Di Raimondo, F. Macro, M. Liberati, A.M. Pawlyn, C. Offidani, M. Spencer, A. Hájek, R. Terpos, E. Morgan, G.J. Bladé, J. Sonneveld, P. San-Miguel, J. McCarthy, P.L. Ludwig, H. Boccadoro, M. Mateos, M.-. Attal, M. (2018). Maintenance Treatment and Survival in Patients With Myeloma. Jama oncology, Vol.4 (10), pp. 1389-1389.

Fok, J.H. Hedayat, S. Zhang, L. Aronson, L.I. Mirabella, F. Pawlyn, C. Bright, M.D. Wardell, C.P. Keats, J.J. De Billy, E. Rye, C.S. Chessum, N.E. Jones, K. Morgan, G.J. Eccles, S.A. Workman, P. Davies, F.E. (2018). HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target. Clinical cancer research : an official journal of the american association for cancer research, Vol.24 (10), pp. 2395-2407.  show abstract

Pawlyn, C. Davies, F.E. (2018). Molecular profiling in myeloma. Hemasphere, Vol.2, pp. 118-120.

Pawlyn, C. Loehr, A. Ashby, C. Tytarenko, R. Deshpande, S. Sun, J. Fedorchak, K. Mughal, T. Davies, F.E. Walker, B.A. Morgan, G.J. (2018). Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?. Leukemia, Vol.32 (7), pp. 1561-1566.  show abstract

Bødker, J.S. Brøndum, R.F. Schmitz, A. Schönherz, A.A. Jespersen, D.S. Sønderkær, M. Vesteghem, C. Due, H. Nørgaard, C.H. Perez-Andres, M. Samur, M.K. Davies, F. Walker, B. Pawlyn, C. Kaiser, M. Johnson, D. Bertsch, U. Broyl, A. van Duin, M. Shah, R. Johansen, P. Nørgaard, M.A. Samworth, R.J. Sonneveld, P. Goldschmidt, H. Morgan, G.J. Orfao, A. Munshi, N. Johnson, H.E. El-Galaly, T. Dybkær, K. Bøgsted, M. (2018). A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis. Blood advances, Vol.2 (18), pp. 2400-2411.  show abstract

Boyle, E.M. Ashby, C. Wardell, C.P. Rowczenio, D. Sachchithanantham, S. Wang, Y. Johnson, S.K. Bauer, M.A. Weinhold, N. Kaiser, M.F. Johnson, D.C. Jones, J.R. Pawlyn, C. Proszek, P. Schinke, C. Facon, T. Dumontet, C. Davies, F.E. Morgan, G.J. Walker, B.A. Wechalekar, A.D. (2018). The genomic landscape of plasma cells in systemic light chain amyloidosis. Blood, Vol.132 (26), pp. 2775-2777.

Sriskandarajah, P. Pawlyn, C. Mohammed, K. Dearden, C.E. Davies, F.E. Morgan, G.J. Boyd, K.D. Kaiser, M.F. (2017). The efficacy and tolerability of pomalidomide in relapsed/refractory myeloma patients in a "real-world" study: the Royal Marsden Hospital experience. Leukemia & lymphoma, Vol.58 (2), pp. 494-497.

Tumber, A. Nuzzi, A. Hookway, E.S. Hatch, S.B. Velupillai, S. Johansson, C. Kawamura, A. Savitsky, P. Yapp, C. Szykowska, A. Wu, N. Bountra, C. Strain-Damerell, C. Burgess-Brown, N.A. Ruda, G.F. Fedorov, O. Munro, S. England, K.S. Nowak, R.P. Schofield, C.J. La Thangue, N.B. Pawlyn, C. Davies, F. Morgan, G. Athanasou, N. Müller, S. Oppermann, U. Brennan, P.E. (2017). Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells. Cell chemical biology, Vol.24 (3), pp. 371-380.

Rasche, L. Angtuaco, E. McDonald, J.E. Buros, A. Stein, C. Pawlyn, C. Thanendrarajan, S. Schinke, C. Samant, R. Yaccoby, S. Walker, B.A. Epstein, J. Zangari, M. van Rhee, F. Meissner, T. Goldschmidt, H. Hemminki, K. Houlston, R. Barlogie, B. Davies, F.E. Morgan, G.J. Weinhold, N. (2017). Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma. Blood, Vol.130 (1), pp. 30-34.  show abstract

Pawlyn, C. Morgan, G.J. (2017). Evolutionary biology of high-risk multiple myeloma. Nature reviews. cancer, Vol.17 (9), pp. 543-556.  show abstract

Johnson, D.C. Lenive, O. Mitchell, J. Jackson, G. Owen, R. Drayson, M. Cook, G. Jones, J.R. Pawlyn, C. Davies, F.E. Walker, B.A. Wardell, C. Gregory, W.M. Cairns, D. Morgan, G.J. Houlston, R.S. Houlston, R.S. Kaiser, M.F. (2017). Neutral tumor evolution in myeloma is associated with poor prognosis. Blood, Vol.130 (14), pp. 1639-1643.  show abstract

Stein, C.K. Pawlyn, C. Chavan, S. Rasche, L. Weinhold, N. Corken, A. Buros, A. Sonneveld, P. Jackson, G.H. Landgren, O. Mughal, T. He, J. Barlogie, B. Bergsagel, P.L. Davies, F.E. Walker, B.A. Morgan, G.J. (2017). The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma. Oncotarget, Vol.8 (17), pp. 27854-27867.

Pawlyn, C. Bright, M.D. Buros, A.F. Stein, C.K. Walters, Z. Aronson, L.I. Mirabella, F. Jones, J.R. Kaiser, M.F. Walker, B.A. Jackson, G.H. Clarke, P.A. Bergsagel, P.L. Workman, P. Chesi, M. Morgan, G.J. Davies, F.E. (2017). Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood cancer journal, Vol.7 (3), pp. e549-?.  show abstract

Jones, J.R. Pawlyn, C. Davies, F.E. Morgan, G.J. (2016). The safety of pomalidomide for the treatment of multiple myeloma. Expert opinion on drug safety, Vol.15 (4), pp. 535-547.

Wale, A. Pawlyn, C. Kaiser, M. Messiou, C. (2016). Frequency, distribution and clinical management of incidental findings and extramedullary plasmacytomas in whole body diffusion weighted magnetic resonance imaging in patients with multiple myeloma. Haematologica, Vol.101 (4), pp. e142-e144.

Pawlyn, C. Fowkes, L. Otero, S. Jones, J.R. Boyd, K.D. Davies, F.E. Morgan, G.J. Collins, D.J. Sharma, B. Riddell, A. Kaiser, M.F. Messiou, C. (2016). Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?. Leukemia, Vol.30 (6), pp. 1446-1448.

Pawlyn, C. Gay, F. Larocca, A. Roy, V. Ailawadhi, S. (2016). Nuances in the Management of Older People With Multiple Myeloma. Current hematologic malignancy reports, Vol.11 (3), pp. 241-251.  show abstract

Jones, J.R. Cairns, D.A. Gregory, W.M. Collett, C. Pawlyn, C. Sigsworth, R. Striha, A. Henderson, R. Kaiser, M.F. Jenner, M. Cook, G. Russell, N.H. Williams, C. Pratt, G. Kishore, B. Lindsay, J. Drayson, M.T. Davies, F.E. Boyd, K.D. Owen, R.G. Jackson, G.H. Morgan, G.J. (2016). Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial. Blood cancer journal, Vol.6 (12), pp. e506-?.  show abstract

Pawlyn, C. Kaiser, M.F. Heuck, C. Melchor, L. Wardell, C.P. Murison, A. Chavan, S.S. Johnson, D.C. Begum, D.B. Dahir, N.M. Proszek, P.Z. Cairns, D.A. Boyle, E.M. Jones, J.R. Cook, G. Drayson, M.T. Owen, R.G. Gregory, W.M. Jackson, G.H. Barlogie, B. Davies, F.E. Walker, B.A. Morgan, G.J. (2016). The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma. Clinical cancer research : an official journal of the american association for cancer research, Vol.22 (23), pp. 5783-5794.  show abstract

Otero, S. Kaiser, M. Pawlyn, C. Giles, S. Scurr, E. Messiou, C. (2015). Patient experience of whole body diffusion weighted magnetic resonance imaging (WB-MRI) for staging myeloma. Cancer imaging, Vol.15 (S1).

Pawlyn, C. Melchor, L. Murison, A. Wardell, C.P. Brioli, A. Boyle, E.M. Kaiser, M.F. Walker, B.A. Begum, D.B. Dahir, N.B. Proszek, P. Gregory, W.M. Drayson, M.T. Jackson, G.H. Ross, F.M. Davies, F.E. Morgan, G.J. (2015). Coexistent hyperdiploidy does not abrogate poor prognosis in myeloma with adverse cytogenetics and may precede IGH translocations. Blood, Vol.125 (5), pp. 831-840.  show abstract

Walker, B.A. Boyle, E.M. Wardell, C.P. Murison, A. Begum, D.B. Dahir, N.M. Proszek, P.Z. Johnson, D.C. Kaiser, M.F. Melchor, L. others, (2015). Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma. Journal of clinical oncology, Vol.33, pp. 3911-3920.

Walker, B.A. Wardell, C.P. Murison, A. Boyle, E.M. Dahir, N.M. Proszek, P.Z. Melchor, L. Pawlyn, C. Kaiser, M.F. Johnson, D.C. others, (2015). APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nature communications, Vol.6.

Brioli, A. Melchor, L. Titley, I. Vijayaraghavan, G. Stephens, C. Zeisig, A. Pawlyn, C. Cavo, M. Morilla, R. Davies, F.E. Morgan, G.J. (2014). The impact of long-term lenalidomide exposure on the cellular composition of bone marrow. Leukemia & lymphoma, Vol.55 (11), pp. 2665-2668.

Pawlyn, C. Kaiser, M.F. Davies, F.E. Morgan, G.J. (2014). Current and potential epigenetic targets in multiple myeloma. Epigenomics, Vol.6 (2), pp. 215-228.  show abstract

Pawlyn, C. Hookway, E. Cain, P. Pliuskys, L. Kaiser, M.F. Bright, M. Aronson, L.I. Murison, A. Lindow, M. Obad, S. Oerum, H. Opperman, U. Morgan, G.J. Davies, F.E. (2014). Histone Demethylase Inhibition As a Novel Therapeutic Strategy in Myeloma. Blood, Vol.124 (21).

Pawlyn, C. Khan, M.S. Muls, A. Sriskandarajah, P. Kaiser, M.F. Davies, F.E. Morgan, G.J. Andreyev, H.J. (2014). Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood, Vol.124 (15), pp. 2467-2468.

Brioli, A. Giles, H. Pawlyn, C. Campbell, J.P. Kaiser, M.F. Melchor, L. Jackson, G.H. Gregory, W.M. Owen, R.G. Child, J.A. Davies, F.E. Cavo, M. Drayson, M.T. Morgan, G.J. (2014). Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood, Vol.123 (22), pp. 3414-3419.  show abstract

Brioli, A. Boyd, K.D. Kaiser, M.F. Pawlyn, C. Wu, P. Gregory, W.M. Owen, R. Ross, F.M. Jackson, G.H. Cavo, M. Davies, F.E. Morgan, G.J. (2013). Response and biological subtype of myeloma are independent prognostic factors and combine to define outcome after high-dose therapy. British journal of haematology, Vol.161 (2), pp. 291-294.

Brioli, A. Kaiser, M.F. Pawlyn, C. Wu, P. Gregory, W.M. Owen, R. Ross, F.M. Jackson, G.H. Cavo, M. Davies, F.E. Morgan, G.J. (2013). Biologically defined risk groups can be used to define the impact of thalidomide maintenance therapy in newly diagnosed multiple myeloma. Leukemia & lymphoma, Vol.54 (9), pp. 1975-1981.

Nagendran, S.T. Pawlyn, C. Brown, M. Pelosini, L. (2012). Crystalline keratopathy associated with monoclonal gammopathy of undetermined significance. British journal of haematology, Vol.159 (3), pp. 258-258.

Boyd, K.D. Pawlyn, C. Morgan, G.J. Davies, F.E. (2012). Understanding the molecular biology of myeloma and its therapeutic implications. Expert review of hematology, Vol.5 (6), pp. 603-617.

Mirabella, F. Murison, A. Aronson, L.I. Wardell, C.P. Thompson, A.J. Hanrahan, S.J. Fok, J.H. Pawlyn, C. Kaiser, M.F. Walker, B.A. Davies, F.E. Morgan, G.J. A Novel Functional Role for MMSET in RNA Processing Based on the Link Between the REIIBP Isoform and Its Interaction with the SMN Complex. Plos one, Vol.9 (6), pp. e99493-e99493.

Jones, J.R. Barber, A. Le Bihan, Y.-. Weinhold, N. Ashby, C. Walker, B.A. Wardell, C.P. Wang, H. Kaiser, M.F. Jackson, G.H. Davies, F.E. Chopra, R. Morgan, G.J. Pawlyn, C. Mutations in CRBN and other cereblon pathway genes are infrequently associated with acquired resistance to immunomodulatory drugs. Leukemia, Vol.35 (10), pp. 3017-3020.

Bird, S.A. Jackson, G.H. Pawlyn, C. Maintenance Strategies Post-Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma. Clinical hematology international, Vol.2 (2), pp. 59-59.

de Tute, R.M. Pawlyn, C. Cairns, D.A. Davies, F.E. Menzies, T. Rawstron, A. Jones, J.R. Hockaday, A. Henderson, R. Cook, G. Drayson, M.T. Jenner, M.W. Kaiser, M.F. Gregory, W.M. Morgan, G.J. Jackson, G.H. Owen, R.G. Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk. Journal of clinical oncology, .  show abstract

Davies, F.E. Pawlyn, C. Usmani, S.Z. San-Miguel, J.F. Einsele, H. Boyle, E.M. Corre, J. Auclair, D. Cho, H.J. Lonial, S. Sonneveld, P. Stewart, A.K. Bergsagel, P.L. Kaiser, M.F. Weisel, K. Keats, J.J. Mikhael, J.R. Morgan, K.E. Ghobrial, I.M. Orlowski, R.Z. Landgren, C.O. Gay, F. Caers, J. Chng, W.J. Chari, A. Walker, B.A. Kumar, S.K. Costa, L.J. Anderson, K.C. Morgan, G.J. Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood cancer discovery, , pp. OF1-OF12.  show abstract


Conferences

Eccleston, M.E.Williams, S.L.Yue, Z.Chen, R.Lee, C.K.Anikina, E.Pawlyn, C.Barrand, M.A.Slater, N.K. (2005). Design and In-vitro Testing of Effective Poly(l-Lysine Iso-Phthalamide) Based Drug Targeting Systems for Solid Tumours, Food and Bioproducts Processing, Vol.83 (2), pp.141-146.

In this section

Publications